drugset / Trial / NCT03526432
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of this drug combination will be assessed to see what effect this treatment has on this patient population.
Timeline
- Start
- 2018-08-08
- Primary completion
- 2026-06-30
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |